Cargando…
Production and characterization of a novel long-acting Herceptin-targeted nanobubble contrast agent specific for Her-2-positive breast cancers
BACKGROUND: There is an unmet need for specific and sensitive imaging techniques to assess the efficacy of breast cancer therapy, particularly Her-2-expressing cancers. Ultrasonic microbubbles are being developed for use as diagnostic and therapeutic tools. However, nanobubbles circulate longer, are...
Autores principales: | Jiang, Qiongchao, Hao, Shaoyun, Xiao, Xiaoyun, Yao, Jiyi, Ou, Bing, Zhao, Zizhuo, Liu, Fengtao, Pan, Xin, Luo, Baoming, Zhi, Hui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839059/ https://www.ncbi.nlm.nih.gov/pubmed/25691133 http://dx.doi.org/10.1007/s12282-014-0581-8 |
Ejemplares similares
-
Kinetic Modeling of DUSP Regulation in Herceptin-Resistant HER2-Positive Breast Cancer
por: Buiga, Petronela, et al.
Publicado: (2019) -
The Optimized Fabrication of Nanobubbles as Ultrasound Contrast Agents for Tumor Imaging
por: Cai, Wen Bin, et al.
Publicado: (2015) -
Herceptin-sensitivity of HER2-transgenic mouse mammary tumors
por: Schwall, RH, et al.
Publicado: (2003) -
Serological Her2/neu-determination in patients receiving Herceptin(®)
por: Thomas, A, et al.
Publicado: (2001) -
Characterization of the interaction of nanobubble ultrasound contrast agents with human blood components
por: Cooley, Michaela B., et al.
Publicado: (2022)